Antibody profiling with protein antigen microarrays in early stage cancer

Expert Opinion on Medical Diagnostics

Volumn 6, Issue 3, 2012, Pages 187-196

  Liu, Brian C S ^a   Dijohnson, Daniel A ^a   O'Rourke, Dennis J ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Antigen microarray; Autoantibody profiling; Biomarker; Cancer diagnostic; Humoral response; Native antigen microarray; Natural antigen microarray; Protein microarray; Reverse capture microarray; Serologic detection

Indexed keywords

ALPHA FETOPROTEIN; AUTOANTIBODY; BIOLOGICAL MARKER; CANCER VACCINE; COMPLEMENTARY DNA; HAPTOGLOBIN; IMMUNOGLOBULIN G ANTIBODY; MESSENGER RNA; MONOCLONAL ANTIBODY; RECOMBINANT PROTEIN;

ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIGEN ANTIBODY REACTION; BACTERIOPHAGE; BREAST CANCER; CANCER IMMUNIZATION; CANCER SCREENING; CANCER STAGING; CELL ADHESION; CELL MIGRATION; DRUG EFFICACY; EARLY CANCER; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPRESSION VECTOR; GLYCOSYLATION; HUMAN; HUMORAL IMMUNITY; HYDROPHOBICITY; LIQUID CHROMATOGRAPHY; LUNG CANCER; LUNG NON SMALL CELL CANCER; MOLECULAR DYNAMICS; OVARY CANCER; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN EXPRESSION; PROTEIN MICROARRAY; PROTEIN MODIFICATION; PROTEIN PROTEIN INTERACTION; PROTEIN PURIFICATION; REPRODUCIBILITY; REVIEW; SIGNAL NOISE RATIO; SIGNAL TRANSDUCTION;

EID: 84860231769     PISSN: 17530059     EISSN: 17530067     Source Type: Journal    
DOI: 10.1517/17530059.2012.672969     Document Type: Review

References (45)

1. Finn OJ. Immune response as a biomarker for cancer detection and a lot more. N Engl J Med 2005;353:1288-90
2. Liang T, Hiipakka RA, Stebbins J, Liao S. Anti-5-alpha-reductase autoantibodies in the serum of patients with prostatic cancer. J Clin Endocrinol Metab 1990;71:1666-8
3. Lang C, Unteregger G, Kartarius S, et al. p53 autoantibodies in patients with urological tumours. Br J Urol 1998;82:721-6
4. Nilsson BO, Carlsson L, Larsson A, Ronquist G. Autoantibodies to prostasomes as new markers for prostate cancer. Ups J Med Sci 2001;106:43-39
5. Mintz PJ, Kim J, Do K-A, et al. Fingerprinting the circulating repertoire of antibodies from cancer patients. Nat Biotechnol 2003;21:57-63
6. Mollick JA, Hoki FS, Soiffer RJ, et al. MUC-1 like tandem repeat proteins are broadly immunogenic in cancer patients. Cancer Immunol 2003;3:3
7. Taylor DD, Gercel-Taylor C, Parker LP. Patient-derived tumor-reactive antibodies as diagnostic markers for ovarian cancer. Gynecol Oncol 2009;115:112-20
8. Tan EM. Autoantibodies as reporters identifying aberrant cellular mechanisms in tumorigenesis. J Clin Invest 2001;108:1411-15
9. Zhang J-Y, Casiano CA, Peng X-X, et al.Enhancement of antibody detection in cancer using panel of recombinant tumorassociated antigens. Cancer Epidemiol Biomarkers Prev 2003;12:136-43
10. Zhang J-Y. Tumor-associated antigen arrays to enhance antibody detection for cancer diagnosis. Cancer Detect Prev 2004;28:114-18
11. Sahin U, Tureci O, Schmitt H, et al. Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci USA 1995;92:11810-13
12. Tureci O, Sahin U, Pfreundschuh M. Serological analysis of human tumor antigens: molecular definition and implications. Mol Med Today 1997;3:342-9
13. Li G, Miles A, Line A, Rees RC. Identification of tumour antigens by serological analysis of cDNA expression cloning. Cancer Immunol Immunother 2004;53:139-43 Available from http://ludwig-sun5.unil. ch/CancerImmunomeDB
14. Shimizu K, Katoh H, Yamashita F, et al. Comparison of carbohydrate structures of serum alpha-fetoprotein by sequential glycosidase digestion and lectin affinity electrophoresis. Clin Chim Acta 1996;254:23-40
15. Thompson S, Cantwell BM, Cornell C, Turner GA. Abnormally-fucosylated haptoglobin: a cancer marker for tumour burden but not gross liver metastasis. Br J Cancer 1991;64:386-90
16. Van Dijk W, Havenaar EC, Brinkman-van der Linden EC. Alpha 1-acid glycoprotein (orosomucoid): pathophysiological changes in glycosylation in relation to its function. Glycoconj J 1995;12:227-33
17. Thompson S, Guthrie D, Turner GA. Fucosylated forms of alpha-1-antitrypsin that predict unresponsiveness to chemotherapy in ovarian cancer. Br J Cancer 1988;58:589-93
18. Reis CA, David L, Seixas M, et al. Expression of fully and under-glycosylated forms of MUC1 mucin in gastric carcinoma. Int J Cancer 1998;79:402-10
19. Lloyd KO, Burchell J, Kudryashov V, et al. Comparison of O-linked carbohydrate chains in MUC-1 mucin from normal breast epithelial cell lines and breast carcinoma cell lines. Demonstration of simpler and fewer glycan chains in tumor cells. J Biol Chem 1996;271:33325-34
20. Gunawardana CG, Diamandis EP. High throughput proteomic strategies for identifying tumour-associated antigens. Cancer Lett 2007;249:110-19
21. Wang X, Yu J, Sreekumar A, et al. Autoantibody signatures in prostate cancer. N Engl J Med 2005;353:1224-35
22. Zhong L, Coe SP, Stromberg AJ, et al. Profiling tumor-associated antibodies for early detection of non-small cell lung cancer. J Thorac Oncol 2006;1:513-19
23. Chatterjee M, Mohapatra S, Ionan A, et al. Diagnostic markers of ovarian cancer by high-throughput antigen cloning and detection on arrays. Cancer Res 2006;66:1181-90
24. Zhong L, Ge K, Zu JC, et al. Autoantibodies as potential biomarkers for breast cancer. Breast Cancer Res 2008;10:R40
25. Available from: www.invitrogen.com
26. Hudson ME, Pozdnyakova I, Haines K, et al. Identification of differentially expressed proteins in ovarian cancer using high-density protein microarrays. Proc Natl Acad Sci USA 2007;104:17494-9
27. Gunawardana CG, Memari N, Diamandis EP. Identifying novel autoantibody signatures in ovarian cancer using high-density protein microarrays. Clin Biochem 2009;42:426-9
28. Gnjatic S, Ritter E, Suchler MW, et al. Seromic profiling of ovarian and pancreatic cancer. Proc Natl Acad Sci USA 2010;107:5088-93
29. Babel I, Barderas R, Diaz-Uriarte R, et al. Identification of tumor-associated autoantigens for the diagnosis of colorectal cancer in serum using high density protein microarrays. Mol Cell Proteomics 2009; 8:2382-95
30. Ehrlich JR, Caiazzo RJ Jr, Qiu W, et al. A native antigen "reverse capture" microarray platform for autoantibody profiling of prostate cancer sera. Proteomics Clin Appl 2007;1:476-85
31. Ehrlich JR, Qin S, Liu BCS. The "reverse capture" autoantibody microarray: a native antigen-based platform for autoantibody profiling. Nat Protoc 2006;1:452-60
32. O'Rourke DJ, DiJohnson DA, Caiazzo RJ, et al. Autoantibody signatures as biomarkers to distinguish prostate cancer from benign prostatic hyperplasia in patients with elevated serum prostate specific antigen. Clin Chim Acta 2012;413:561-7
33. Tang L, Yang J, Ng S-K, et al. Autoantibody profiling to identify biomarkers of key pathogenic pathways in mucinous ovarian cancer. Eur J Cancer 2010;46:170-9
34. Cramer DW, O'Rourke DJ, Vitonis AF, et al. CA125 immune complexes in ovarian cancer patients with low CA125 concentrations. Clin Chem 2010;56:1889-92
35. Qiu J, Madoz-Gurpide J, Misek DE, et al. Development of natural protein microarrays for diagnosing cancer based on an antibody response to tumor antigens. J Proteome Res 2004;3:261-7
36. Bouwman K, Qiu J, Zhou H, et al. Microarrays of tumor cell derived proteins uncover a distinct pattern of prostate cancer serum immunoreactivity. Proteomics 2003;3:2200-7
37. Caiazzo RJ Jr, O'Rourke DJ, Barker TJ, et al. Native antigen fractionation protein microarrays for biomarker discovery. Methods Mol Biol 2011;723:129-48
38. Groathouse NA, Amin A, Marques MAM, et al. Use of protein microarrays to define the humoral immune response in leprosy patients and identification of disease-state-specific antigenic profiles. Infect Immun 2006;74:6458-66
39. Wandall HH, Blixt O, TarpMA, et al. Cancer biomarkers defined by autoantibody signatures to aberrant O-glycopeptide epitopes. Cancer Res 2010;70:1306-13
40. Sanchez-Carbayo M. Antibody arrays: technical considerations and clinical applications in cancer. Clin Chem 2006;52:1651-9
41. Angenendt P, Glokler J, Murphy D, et al. Toward optimized antibody microarrays: a comparison of current microarray support materials. Anal Biochem 2002;309:253-60
42. Angenendt P, Glokler J, Sobek J, et al. Next generation of protein microarray support materials: evaluation for protein and antibody microarray applications. J Chromatogr A 2003;1009:97-104
43. Kijanka G, Murphy D. Protein arrays as tools for serum autoantibody marker discovery in cancer. J Proteomics 2009;72:936-44
44. Kricka LJ, Master SR. Validation and quality control of protein microarray-based analytical methods. Mol Biotechnol 2008;38:19-31
45. Copeland S, Siddiqui J, Remick D. Direct comparison of traditional ELISAs and membrane protein arrays for detection and quantification of human cytokines. J Immunol Methods 2004;284:99-106